Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Weldon, William C ^a   Zarnitsyn, Vladimir G ^b   Esser, E Stein ^a   Taherbhai, Misha T ^a   Koutsonanos, Dimitrios G ^a   Vassilieva, Elena V ^a   Skountzou, Ioanna ^a   Prausnitz, Mark R ^b   Compans, Richard W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Georgia Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMIQUIMOD; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; FEMALE; HEMAGGLUTINATION INHIBITION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MATERIAL COATING; MICRONEEDLE; MONOTHERAPY; MOUSE; NEEDLE; NONHUMAN; VIRUS INHIBITION;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; FEMALE; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; MICE; MICE, INBRED BALB C; POLY I-C; VACCINATION; VACCINES, SUBUNIT;

MUS;

EID: 84864338584     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041501     Document Type: Article

References (52)

1. Centers for Disease Control and Prevention (2011) Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 60: 1128-1132.
2. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, et al. (2009) Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 28: 563-571.
3. Fragapane E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, et al. (2010) A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin Vaccine Immunol 17: 1817-1819.
4. Petrovsky N, Aguilar JC, (2004) Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82: 488-496.
5. El Sahly H, (2010) MF59™; as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines 9: 1135-1141.
6. Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK, et al. (2001) Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol 166: 249-255.
7. Jelinek I, Leonard JN, Price GE, Brown KN, Meyer-Manlapat A, et al. (2011) TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J Immunol 186: 2422-2429.
8. Kaisho T, Takeuchi O, Kawai T, Hoshino K, Akira S, (2001) Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol 166: 5688-5694.
9. Larange A, Antonios D, Pallardy M, Kerdine-Romer S, (2009) TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. J Leukoc Biol 85: 673-683.
10. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM, (2004) Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351: 2295-2301.
11. Kim YC, Jarrahian C, Zehrung D, Mitragotri S, Prausnitz MR, (2012) Delivery systems for intradermal vaccination. Curr Top Microbiol Immunol 351: 77-112.
12. Flynn PM, Shenep JL, Mao L, Crawford R, Williams BF, et al. (1994) Influence of needle gauge in Mantoux skin testing. Chest 106: 1463-1465.
13. Lambert PH, Laurent PE, (2008) Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 26: 3197-3208.
14. Atmar RL, Patel SM, Keitel WA, (2010) Intanza((R)): a new intradermal vaccine for seasonal influenza. Expert Rev Vaccines 9: 1399-1409.
15. Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, Sullivan SP, Compans RW, et al. (2009) Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One 4: e4773.
16. Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, et al. (2009) Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine 27: 6932-6938.
17. Weldon WC, Martin MP, Zarnitsyn V, Wang B, Koutsonanos D, et al. (2011) Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin Vaccine Immunol 18: 647-654.
18. Andrianov AK, DeCollibus DP, Gillis HA, Kha HH, Marin A, et al. (2009) Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. Proc Natl Acad Sci U S A 106: 18936-18941.
19. Slutter B, Bal SM, Ding Z, Jiskoot W, Bouwstra JA, (2011) Adjuvant effect of cationic liposomes and CpG depends on administration route. J Control Release 154: 123-130.
20. Bal SM, Slutter B, Verheul R, Bouwstra JA, Jiskoot W, (2012) Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice. Eur J Pharm Sci 45: 475-481.
21. Corbett HJ, Fernando GJ, Chen X, Frazer IH, Kendall MA, (2010) Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. PLoS One 5: e13460.
22. Chen D, Endres R, Maa YF, Kensil CR, Whitaker-Dowling P, et al. (2003) Epidermal powder immunization of mice and monkeys with an influenza vaccine. Vaccine 21: 2830-2836.
23. Holmgren J, Adamsson J, Anjuere F, Clemens J, Czerkinsky C, et al. (2005) Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 97: 181-188.
24. Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, et al. (1998) Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol 161: 3211-3214.
25. Akira S, Takeda K, Kaisho T, (2001) Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2: 675-680.
26. Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, et al. (2006) Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13: 981-990.
27. Hobson D, Curry RL, Beare AS, Ward-Gardner A, (1972) The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 70: 767-777.
28. Reinhardt RL, Liang HE, Locksley RM, (2009) Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol 10: 385-393.
29. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, et al. (2003) CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421: 852-856.
30. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, et al. (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12: 1203-1207.
31. Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, et al. (2011) Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 146: 980-991.
32. Schneider-Ohrum K, Giles BM, Weirback HK, Williams BL, DeAlmeida DR, et al. (2011) Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice. Vaccine 29: 9081-9092.
33. Barrett PN, Ehrlich HJ, (2011) Adjuvanted or whole-virion vaccine for 2009 influenza A (H1N1). Lancet Infect Dis 11: 496-497; author reply 497-498.
34. Launay O, Desaint C, Durier C, Loulergue P, Duval X, et al. (2011) Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis 204: 124-134.
35. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, et al. (2011) Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 365: 1406-1416.
36. Gill HS, Denson DD, Burris BA, Prausnitz MR, (2008) Effect of microneedle design on pain in human volunteers. Clin J Pain 24: 585-594.
37. Coffman RL, Savelkoul HF, Lebman DA, (1989) Cytokine regulation of immunoglobulin isotype switching and expression. Semin Immunol 1: 55-63.
38. Schroder K, Hertzog PJ, Ravasi T, Hume DA, (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75: 163-189.
39. Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, et al. (2007) Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445: 319-323.
40. La Gruta NL, Kedzierska K, Stambas J, Doherty PC, (2007) A question of self-preservation: immunopathology in influenza virus infection. Immunol Cell Biol 85: 85-92.
41. Mitsui H, Watanabe T, Saeki H, Mori K, Fujita H, et al. (2004) Differential expression and function of Toll-like receptors in Langerhans cells: comparison with splenic dendritic cells. J Invest Dermatol 122: 95-102.
42. Fujita H, Asahina A, Mitsui H, Tamaki K, (2004) Langerhans cells exhibit low responsiveness to double-stranded RNA. Biochem Biophys Res Commun 319: 832-839.
43. Hasan M, Ruksznis C, Wang Y, Leifer CA, (2011) Antimicrobial peptides inhibit polyinosinic-polycytidylic acid-induced immune responses. J Immunol 187: 5653-5659.
44. Dorschner RA, Pestonjamasp VK, Tamakuwala S, Ohtake T, Rudisill J, et al. (2001) Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol 117: 91-97.
45. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, et al. (2000) Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 114: 135-141.
46. Koutsonanos DG, Vassilieva EV, Stavropoulou A, Zarnitsyn VG, Esser ES, et al. (2012) Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci Rep 2: 357.
47. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, et al. (2009) Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 361: 2424-2435.
48. Dormitzer PR, Rappuoli R, Casini D, O'Hagan D, Runham C, et al. (2009) Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice. PLoS Curr 1: RRN1025.
49. Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR, (2010) Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release 142: 187-195.
50. Gill HS, Prausnitz MR, (2007) Coated microneedles for transdermal delivery. J Control Release 117: 227-237.
51. Sha Z, Compans RW, (2000) Induction of CD4(+) T-cell-independent immunoglobulin responses by inactivated influenza virus. J Virol 74: 4999-5005.
52. World Health Organization (2002) WHO manual on animal influenza diagnosis and surveillance. http://www.wpro.who.int/NR/rdonlyres/EFD2B9A7-2265-4AD0-BC98-97937B4FA83C/0/manualonanimalaidiagnosisandsurveillance.pdf.